Hereditary haemorrhagic telangiectasia
Drug research and approvals for hereditary haemorrhagic telangiectasia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 22, 2026, 17 studies of hereditary haemorrhagic telangiectasia are recruiting on ClinicalTrials.gov, and Health Canada has authorized 9 drug trials for it since 2013.
- Recruiting worldwide: 17
- Trials authorized in Canada: 9
- FDA orphan approvals: 0
- EU medicines: 0
- Bevacizumab in the Treatment of HHTNCT07828015 · Phase 2 · Second Affiliated Hospital, Zhejiang University, School of Medicine · starts May 1, 2025
- Body Donation in HHTNCT07826845 · Not applicable · University Hospital, Essen · starts Oct 1, 2025
- A Trial to Assess the Efficacy and Safety of Engasertib in Participants With Moderate to Severe Hereditary Hemorrhagic…NCT07743671 · Phase 3 · Vaderis Therapeutics AG · starts Nov 2, 2026
- DIAG723 in Adults With Hereditary Hemorrhagic TelangiectasiaNCT07623525 · Phase 1 / Phase 2 · Diagonal Therapeutics, Inc. · starts Jun 4, 2026
- Harmony-HHT: ATV-1601 in Participants With Hereditary Hemorrhagic Telangiectasia (HHT)NCT07601425 · Phase 1 / Phase 2 · Atavistik Bio, Inc · starts Jul 27, 2026
- Quality of Life in Pediatric Participants With HHTNCT07474428 · Not reported · Ashley Nelson · starts Sep 1, 2026
- Non-Invasive Detection of Pulmonary Right-to-Left Shunts Using the SONAS Ultrasound DeviceNCT07414446 · Not applicable · St. Antonius Hospital · starts Jan 7, 2026
- Immunological Effects of Iron Supplementation in HHT DiseaseNCT07111598 · Not applicable · Hospices Civils de Lyon · starts Sep 24, 2025
- Institutional Registry of Rare DiseasesNCT06573723 · Not reported · Hospital Italiano de Buenos Aires · starts Jul 1, 2024
| Jul 31, 2026 | A randomized, placebo-controlled, double-blind, proof-of-concept study of ATV-1601 in participants with hereditary hemorrhagic telangiectasia (HHT)ATV-1601 | Atavistik Bio, Inc. | Pending |
| Jul 17, 2026 | A phase 1/2, first-in-human, multicenter, ascending single-dose and multi-dose study to assess the safety of DIAG723, a novel bispecific ALK-1 and bmprii…DIAG723 | Diagonal Therapeutics, Inc. | Pending |
| Jun 18, 2026 | A phase 3, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of engasertib in subjects with moderate to severe hereditary…Engasertib (VAD044) | Vaderis Therapeutics AG | Pending |
| Oct 17, 2024 | A phase 1/2, randomized, double-blind, placebo-controlled 2-part study of the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of single…ALN-6400 / Tranexamic acid | Alnylam Pharmaceuticals | Ongoing |
| Apr 14, 2022 | A randomised, placebo controlled, double blind, multicentre proof of concept study to assess the safety and efficacy of two doses of VAD044 in patients with…VAD044 | Vaderis Therapeutics AG | Pending |
| Sep 8, 2021 | Low-dose sirolimus for nosebleeds in hht: a phase II pilot studySirolimus | St Michaels Hospital | Pending |
| Oct 9, 2019 | Tacrolimus crossover trial for hereditary hemorrhagic telangiectasia (HHT)Tacrolimus | St Michaels Hospital | Pending |
| Sep 26, 2017 | Doxycycline crossover trial for hereditary hemorrhagic telangiectasia (HHT)Doxycycline hyclate | St Michaels Hospital | Ongoing |
| Sep 11, 2014 | A phase II study to evaluate the effects of up to 12 weeks of pazopanib dosing on bleeding in subjects with hereditary haemorrhagic telangiectasia.Pazopanib (GW786034) | GSK | Closed |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA